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We performed single-cell culture analyses as previously described. 14, 47, 48 The individual isolated cells were each sorted into 96-well culture plates using FACSAria (BD Biosciences). We used a light microscope 10-16h after cell sorting to confirm that each well contained only one cell. Following cell expansion after isolation of each clone, we subjected the cells to flow cytometry.
Cell proliferation assay, anchorage-independent growth assay, and sphere-forming assay We inoculated the isolated EGFP + and EGFP − cells differentiated from one EGFP + cell at a density of 1×10 3 cells per well in 96-well culture plates, which were then allowed to grow for 7 days. The cell numbers were determined using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazori um, inner salt (MTS) assay (Cell Titer 96 Aqueous One Solution Reagent, Promega), according to the manufacturer's protocol. After 1 h of incubation, the absorbance value was measured using a plate reader at 490 nm.
To examine the anchorage-independent growth, 1 × 10 4 EGFP + and EGFP − cells were suspended in 2.0 mL of 0.3% agar (Wako) supplemented with culture medium. The 5 cell suspension was layered over the bottom layer of 2.0 mL of 0.6% agar. We counted the colonies 14 days after cell sorting.
To investigate the ability to form cell spheres, 1 × 10 5 EGFP + and EGFP − were seeded in 6-well ultra-low attachment plates (Corning Inc., NY, USA) in serum-free medium. We observed the spheres 5 days after cell sorting.
Reagents and drug resistance assay 5-Fluorouracil (5-FU), TGFb1, and GSK-3b inhibitor CHIR99021 were purchased from Wako and was diluted directly with RPMI-1640 to the desired concentration. TGFb receptor 1 (TGFbR1) inhibitor LY2157299 was obtained from Axon Medchem (Groningen, NL). TGFbR1/R2 inhibitor LY2109761 was purchased from Selleck (Houston, TX, USA). Compounds were dissolved in 100% dimethyl sulfoxide (DMSO; Sigma) and diluted with RPMI-1640 or saline to the desired concentration with a final DMSO concentration of under 0.5%. We investigated the 5-FU resistance of the cells. EGFP + and EGFP − cells were cultured with 5-FU for 96h at concentrations of 1 × 10 −9 , 1 × 10 −7 , 1 × 10 −5 , 1 × 10 −3 , and 1 × 10 −1 M. After the culture, MTS assays were performed to determine the half-maximal inhibitory concentrations (IC50). 6 Xenotransplantation Male 6 to 10-week-old non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice (Charles River Laboratories, Inc., Kanagawa, Japan) were used as recipients for xenotransplantation. The isolated EGFP + or EGFP − cells (1.0 × 10 3 or 1.0 × 10 4 cells) derived from a single EGFP + cell were suspended in 200 µL of a mixture of serum-free medium and Matrigel (BD Biosciences) (1:1 volume). The mixture was injected subcutaneously through a 26-gauge needle into the right and left dorsal areas of anesthetized NOD/SCID mice. We monitored tumor formation and tumor size twice a week, and dissected out the tumors 11 weeks after engraftment.
To investigate the differentiation ability in vivo, we performed serial transplantation. Tumors generated from single-cell-derived EGFP + or EGFP − cells were harvested, and then digested with collagenase solution for 30 min at 37°C. After rinsing the tumors in phosphate-buffered saline (PBS), we analyzed and sorted the cells using the FACSAria. Prior to the second transplantation, the harvested cells were cultured in G418-containing medium for at least 7 days to eliminate cells that originated from the host mice. Thereafter, we sorted these cells according to the EGFP fluorescence, and transplanted 1 × 10 4 EGFP + or EGFP − cells into NOD/SCID mice in the same way as in the first transplantation. Wound healing assay and migration assay Wound healing assays were used to assess capacity for cell motility. We seeded the isolated EGFP + and EGFP − cells differentiated from one EGFP + cell at a density of 1 × 10 6 cells per well in 35-mm culture dishes. On reaching full confluency, the cell layer was scratched with a 10-µL plastic tip and then cultured with low serum (2% fetal bovine serum) culture medium and 10 ng/ml TGFb. Micrographs were taken at 24 h after the scratch.
For migration assays, 8-µm-pore 24-well cell culture plates (Corning Inc.) coated with type I collagen were used. We plated 2.5 × 10 4 EGFP + and EGFP − cells in the upper chamber with serum-free medium and 10 ng/ml TGFb; in the lower chamber, normal culture medium containing 10% fetal bovine serum was added. After 48 h of incubation, the cells on the upper surface of the membrane were removed, and the cells on the lower surface were fixed with 4% paraformaldehyde and stained using the Diff-Quick staining kit (Sysmex, Kobe, Japan). T-cell factor/lymphoid enhancer factor (TCF/LEF) luciferase assay To evaluate the activation of Wnt/beta-catenin pathway in HCC cells, we performed TCF/LEF luciferase assay in addition to immunocytochemistry of activated beta-catenin.
Cignal TCF/LEF Reporter Assay Kit (Qiagen) and Dual-Glo TM Luciferase Assay System (Promega) were used according to the manufacturer's protocols.
Enzyme-linked immunosorbent assays (ELISA)
To measure the serum OPN level of HCC patients, we performed ELISA. Blood samples were collected and stored at 4°C for 1 h. Serum was separated by centrifugation (10,000 g for 10 min) at 4°C, and then stored at −80°C until analysis. We quantitated serum OPN levels, respectively, with the human OPN ELISA kits (Millipore) according to the manufacture's protocols. The OPN concentration was calculated by a standard curve. Each serum sample was tested in duplicate, and the results were averaged to maintain reliability.
Statistical analysis
The statistical analyses were performed using SPSS version 17.0 (SPSS Inc., IL, USA) and GraphPad Prism software version 5.0 (GraphPad Software Inc., San Diego, CA, USA). Student's t-test, F-test, Mann-Whitney U test, Fisher's exact test or chi-squared test, log-rank test, and repeated-measures analyses of variances were used for assessment. The tumor initiating frequency in xenotransplantation was calculated by extreme limiting dilution analysis. 54 The mean ± SD of three or more independent experiments is reported.
Recurrence-free survival (RFS) and overall survival (OS) after the operation were calculated using the Kaplan-Meier method and analyzed with the log-rank test.
Significant variables from the univariate analysis were entered in the multivariate analysis using a Cox regression model with forward stepwise selection. We plotted receiver operating characteristics (ROC) curve for serum OPN level and HCC tumor markers, and calculated area under the ROC curve (AUC). The optimal cutoff value of 12 OPN was calculated using the maximum sum of sensitivity and specificity as well as using the minimum distance to the top-left corner of the ROC curve. Statistical significance was defined as P < 0.05.
Supplemental Table 1 Tumor incidence in initial/serial transplantation initial Abbreviation: SOX9, sex determining region Y-box 9; Tx, transplantation.
Supplemental Table 2 The tumor initiating frequency in HCC cells 
SOX9-OPN-SOX9-OPNLung
Abbreviation: SOX9, sex determining region Y-box 9; OPN, osteopontin.
Supplemental Table 4 Univariate analysis with respect to outcome in the resection group Recurrence-free survival ALT, alanine aminotransferase; AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonists-II; NA, not available; CI, confidence interval.
Supplemental Table 5 Univariate analysis with respect to outcome in the transplantation group
Recurrence-free survival 
